Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats

Anan, Hoda H.; Zidan, Rania A.; Shaheen, Mohammad A.; Fattah, Enas A. Abd El

doi:10.1016/j.jcyt.2016.05.004

Cited by 22 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was demonstrated by detecting Y chromosome of male BMSCs in liver tissue of group III by PCR. Previous researchers mentioned the appearance of injected BMSCs in injured liver ( Zhao et al, (2005) ; Aziz et al, (2007) ; Elkafif et al, (2010) ; El-Mahdi et al, (2014) ; Anan et al, (2016) ; Fikry et al, (2016) ).…”

Section: Discussionmentioning

confidence: 99%

Cell therapy as a new approach on hepatic fibrosis of murine model ofSchistosoma mansoniinfection

Alsulami

2019

Preprint

View full text Add to dashboard Cite

Schistosomiasis is an acute and chronic disease caused by blood flukes (trematode worms) of the genus Schistosoma. Schistosomiasis is disease that are prevalent in or unique to tropical and subtropical regions. Previous studies have shown that the role of bone marrow mesenchymal stem cells (BMSCs) therapy in improvement of hepatic fibrosis. Therefore, the current study was designed to assess the therapeutic role of BMSCs in murine schistosomiasis mansoni. BMSCs derived male mice were intraperitoneal injected into female mice that received S. mansoni cercariae through subcutaneous route. Mice were divided into four groups: negative control group (noninfected non treated); positive control group (infected non treated); BMSCs treated group; and untreated group. Liver histopathology and immunohistochemically were evaluated. BMSC intraperitoneal injection resulted in a significant reduction in liver collagen, granuloma size, and significant increase in OV-6 expression in the Schistosomiasis treated mice group. There was overall improvement of the pathological changes of the liver. The findings support that BMSCs has a regenerative potential in the histopathology and function of the liver tissue by decreasing liver fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell therapy as a new approach on hepatic fibrosis of murine model ofSchistosoma mansoniinfection

Alsulami

2019

Preprint

View full text Add to dashboard Cite

show abstract

“…In this meta-analysis, four studies [16,18,22,26] were included for the assessment of MDA, four [16,18,22,26] for GSH, three [10,16,22] Table 2).…”

Section: Oxidative Stressmentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6-8 days, 10-15 days, ≥42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P=0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P<0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P<0.0001; 6-8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P=0.0005; 10-15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P<0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P=0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2-3 days, 4-5 days, 6-8 days, ≥28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion: MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

“…In this meta-analysis, four studies [16,18,22,26] were included for the assessment of MDA, four [16,18,22,26] for GSH, three [10,16,22] for SOD. The results indicated that the difference between MSCs treatment group and control group was notable for MDA, GSH, SOD (MDA: WMD=-17.21, 95%CI: -20.38, -14.04, P < 0.00001; GSH: WMD = 4.62, 95%CI: 2.74, 6.50, P < 0.00001; SOD: WMD = 5.42, 95%CI: 2.92, 7.93, P < 0.0001; Table 2).…”

Section: Oxidative Stressmentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6–8 days, 10–15 days, ≥ 42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P = 0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P < 0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P < 0.0001; 6–8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P = 0.0005; 10–15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P < 0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P = 0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2–3 days, 4–5 days, 6–8 days, ≥ 28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats

Cited by 22 publications

References 38 publications

Cell therapy as a new approach on hepatic fibrosis of murine model ofSchistosoma mansoniinfection

Cell therapy as a new approach on hepatic fibrosis of murine model ofSchistosoma mansoniinfection

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Contact Info

Product

Resources

About